Science 6 December 1985: Vol. 230. no. 4730, pp. 1132 - 1139 DOI: 10.1126/science.2999974

Prev | Table of Contents | Next

Articles

Mechanisms of Escape from Trastuzumab-mediated ADCC in Esophageal Squamous Cell Carcinoma: Relation to Susceptibility to Perforin-granzyme.

Y. KAWAGUCHI, K. KONO, Y. MIZUKAMI, K. MIMURA, and H. FUJII (2009)
Anticancer Res 29, 2137-2146
 |  Abstract »  |  Full Text »  |  PDF »

HER-2 as a Target for Breast Cancer Therapy.

M. Ignatiadis, C. Desmedt, C. Sotiriou, E. de Azambuja, and M. Piccart (2009)
Clin. Cancer Res. 15, 1848-1852
 |  Full Text »  |  PDF »

Somatic Mutations of ErbB4: SELECTIVE LOSS-OF-FUNCTION PHENOTYPE AFFECTING SIGNAL TRANSDUCTION PATHWAYS IN CANCER.

D. Tvorogov, M. Sundvall, K. Kurppa, M. Hollmen, S. Repo, M. S. Johnson, and K. Elenius (2009)
J. Biol. Chem. 284, 5582-5591
 |  Abstract »  |  Full Text »  |  PDF »

Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists.

A. Carbone, G. Botti, A. Gloghini, G. Simone, M. Truini, M. P. Curcio, P. Gasparini, A. Mangia, T. Perin, S. Salvi, et al. (2008)
J. Mol. Diagn. 10, 527-536
 |  Abstract »  |  Full Text »  |  PDF »

Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts.

J. Sarup, P. Jin, L. Turin, X. Bai, M. Beryt, C. Brdlik, J. N. Higaki, B. Jorgensen, F. W. Lau, P. Lindley, et al. (2008)
Mol. Cancer Ther. 7, 3223-3236
 |  Abstract »  |  Full Text »  |  PDF »

Trastuzumab-Induced Hepatotoxicity.

S. Srinivasan, V. Parsa, C. Y Liu, and J. A Fontana (2008)
Ann. Pharmacother. 42, 1497-1501
 |  Abstract »  |  Full Text »  |  PDF »

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

C. Gravalos and A. Jimeno (2008)
Ann. Onc. 19, 1523-1529
 |  Abstract »  |  Full Text »  |  PDF »

Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression.

C. K. Anders, D. S. Hsu, G. Broadwater, C. R. Acharya, J. A. Foekens, Y. Zhang, Y. Wang, P. K. Marcom, J. R. Marks, P. G. Febbo, et al. (2008)
J. Clin. Oncol. 26, 3324-3330
 |  Abstract »  |  Full Text »  |  PDF »

Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer.

M. Ignatiadis, G. Kallergi, M. Ntoulia, M. Perraki, S. Apostolaki, M. Kafousi, G. Chlouverakis, E. Stathopoulos, E. Lianidou, V. Georgoulias, et al. (2008)
Clin. Cancer Res. 14, 2593-2600
 |  Abstract »  |  Full Text »  |  PDF »

Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity.

Y. Katsumi, Y. Kuwahara, S. Tamura, K. Kikuchi, O. Otabe, K. Tsuchiya, T. Iehara, H. Kuroda, H. Hosoi, and T. Sugimoto (2008)
Clin. Cancer Res. 14, 1192-1199
 |  Abstract »  |  Full Text »  |  PDF »

Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells.

C.-C. Ou, S.-C. Hsu, Y.-H. Hsieh, W.-L. Tsou, T.-C. Chuang, J.-Y. Liu, and M.-C. Kao (2008)
Carcinogenesis 29, 299-306
 |  Abstract »  |  Full Text »  |  PDF »

Antibody and CD8+ T Cell Responses against HER2/neu Required for Tumor Eradication after DNA Immunization with a Flt-3 Ligand Fusion Vaccine.

F. Orlandi, F. M. Venanzi, A. Concetti, H. Yamauchi, S. Tiwari, L. Norton, J. D. Wolchok, A. N. Houghton, and P. D. Gregor (2007)
Clin. Cancer Res. 13, 6195-6203
 |  Abstract »  |  Full Text »  |  PDF »

HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.

S. A. V. Ricardo, F. Milanezi, S. T. Carvalho, D. R. A. Leitao, and F. C. L. Schmitt (2007)
J. Clin. Pathol. 60, 1001-1005
 |  Abstract »  |  Full Text »  |  PDF »

A Polyepitope DNA Vaccine Targeted to Her-2/ErbB-2 Elicits a Broad Range of Human and Murine CTL Effectors to Protect against Tumor Challenge.

A. Scardino, M. Alimandi, P. Correale, S. G. Smith, R. Bei, H. Firat, M. G. Cusi, O. Faure, S. Graf-Dubois, G. Cencioni, et al. (2007)
Cancer Res. 67, 7028-7036
 |  Abstract »  |  Full Text »  |  PDF »

Peptide Vaccines of the HER-2/neu Dimerization Loop Are Effective in Inhibiting Mammary Tumor Growth In Vivo.

S. D. Allen, J. T. Garrett, S. V. Rawale, A. L. Jones, G. Phillips, G. Forni, J. C. Morris, R. G. Oshima, and P. T. P. Kaumaya (2007)
J. Immunol. 179, 472-482
 |  Abstract »  |  Full Text »  |  PDF »

Novel Engineered Trastuzumab Conformational Epitopes Demonstrate In Vitro and In Vivo Antitumor Properties against HER-2/neu.

J. T. Garrett, S. Rawale, S. D. Allen, G. Phillips, G. Forni, J. C. Morris, and P. T. P. Kaumaya (2007)
J. Immunol. 178, 7120-7131
 |  Abstract »  |  Full Text »  |  PDF »

Increasing Anticarcinoma Activity of an Anti-erbB2 Recombinant Immunotoxin by the Addition of an Anti-EpCAM sFv.

B. J. Stish, H. Chen, Y. Shu, A. Panoskaltsis-Mortari, and D. A. Vallera (2007)
Clin. Cancer Res. 13, 3058-3067
 |  Abstract »  |  Full Text »  |  PDF »

Brain Metastases: The HER2 Paradigm.

N. U. Lin and E. P. Winer (2007)
Clin. Cancer Res. 13, 1648-1655
 |  Abstract »  |  Full Text »  |  PDF »

Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.

X. Zhang and A. Chang (2007)
J. Med. Genet. 44, 166-172
 |  Abstract »  |  Full Text »  |  PDF »

Effect of ATM, CHEK2 and ERBB2 TAGSNPs and haplotypes on endometrial cancer risk.

K. Einarsdottir, K. Humphreys, C. Bonnard, Y. Li, Y. Li, K. S. Chia, E. T. Liu, P. Hall, J. Liu, and S. Wedren (2007)
Hum. Mol. Genet. 16, 154-164
 |  Abstract »  |  Full Text »  |  PDF »

Levels of Specific Peptide-HLA Class I Complex Predicts Tumor Cell Susceptibility to CTL Killing.

J. A. Weidanz, T. Nguyen, T. Woodburn, F. A. Neethling, M. Chiriva-Internati, W. H. Hildebrand, and J. Lustgarten (2006)
J. Immunol. 177, 5088-5097
 |  Abstract »  |  Full Text »  |  PDF »

Antitumor Effect of Trastuzumab for Pancreatic Cancer with High HER-2 Expression and Enhancement of Effect by Combined Therapy with Gemcitabine..

K. Kimura, T. Sawada, M. Komatsu, M. Inoue, K. Muguruma, T. Nishihara, Y. Yamashita, N. Yamada, M. Ohira, and K. Hirakawa (2006)
Clin. Cancer Res. 12, 4925-4932
 |  Abstract »  |  Full Text »  |  PDF »

Early Tumor Response to Hsp90 Therapy Using HER2 PET: Comparison with 18F-FDG PET.

P. M. Smith-Jones, D. Solit, F. Afroze, N. Rosen, and S. M. Larson (2006)
J. Nucl. Med. 47, 793-796
 |  Abstract »  |  Full Text »  |  PDF »

Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors..

G. Helguera, J. A. Rodriguez, and M. L. Penichet (2006)
Mol. Cancer Ther. 5, 1029-1040
 |  Abstract »  |  Full Text »  |  PDF »

A Trimeric Anti-HER2/neu ScFv and Tumor Necrosis Factor-{alpha} Fusion Protein Induces HER2/neu Signaling and Facilitates Repair of Injured Epithelia.

T.-H. Huang and S. L. Morrison (2006)
J. Pharmacol. Exp. Ther. 316, 983-991
 |  Abstract »  |  Full Text »  |  PDF »

Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors.

L. Albitar, L. L. Laidler, R. Abdallah, and K. K. Leslie (2005)
Mol. Cancer Ther. 4, 1891-1899
 |  Abstract »  |  Full Text »  |  PDF »

Expression of HER2 and the Coamplified Genes GRB7 and MLN64 in Human Breast Cancer: Quantitative Real-time Reverse Transcription-PCR as a Diagnostic Alternative to Immunohistochemistry and Fluorescence In situ Hybridization.

U. Vinatzer, B. Dampier, B. Streubel, M. Pacher, M. J. Seewald, C. Stratowa, K. Kaserer, and M. Schreiber (2005)
Clin. Cancer Res. 11, 8348-8357
 |  Abstract »  |  Full Text »  |  PDF »

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer..

M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, et al. (2005)
N. Engl. J. Med. 353, 1659-1672
 |  Abstract »  |  Full Text »  |  PDF »

Role of Chromogenic in Situ Hybridization (CISHTM) in the Evaluation of HER2 Status in Breast Carcinoma: Comparison with Immunohistochemistry and Fish.

E. Li-Ning-T, R. Ronchetti, C. Torres-Cabala, and M. J. Merino (2005)
International Journal of Surgical Pathology 13, 343-351
 |  Abstract »  |  PDF »

Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials.

M. F. Press, G. Sauter, L. Bernstein, I. E. Villalobos, M. Mirlacher, J.-Y. Zhou, R. Wardeh, Y.-T. Li, R. Guzman, Y. Ma, et al. (2005)
Clin. Cancer Res. 11, 6598-6607
 |  Abstract »  |  Full Text »  |  PDF »

A Bifunctional Targeted Peptide that Blocks HER-2 Tyrosine Kinase and Disables Mitochondrial Function in HER-2-Positive Carcinoma Cells.

V. R. Fantin, M. J. Berardi, H. Babbe, M. V. Michelman, C. M. Manning, and P. Leder (2005)
Cancer Res. 65, 6891-6900
 |  Abstract »  |  Full Text »  |  PDF »

The immunocytokine scFv23/TNF sensitizes HER-2/neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1.

M.-A. Lyu and M. G. Rosenblum (2005)
Mol. Cancer Ther. 4, 1205-1213
 |  Abstract »  |  Full Text »  |  PDF »

Trastuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity against Esophageal Squamous Cell Carcinoma.

K. Mimura, K. Kono, M. Hanawa, M. Kanzaki, A. Nakao, A. Ooi, and H. Fujii (2005)
Clin. Cancer Res. 11, 4898-4904
 |  Abstract »  |  Full Text »  |  PDF »

The epidermal growth factor receptor family.

L A Bazley and W J Gullick (2005)
Endocr. Relat. Cancer 12, S17-S27
 |  Abstract »  |  Full Text »  |  PDF »

A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis.

J. Norum, T. Risberg, and J. A. Olsen (2005)
Ann. Onc. 16, 909-914
 |  Abstract »  |  Full Text »  |  PDF »

Herceptin Down-Regulates HER-2/neu and Vascular Endothelial Growth Factor Expression and Enhances Taxol-Induced Cytotoxicity of Human Ewing's Sarcoma Cells In vitro and In vivo.

H. Guan, S.-F. Jia, Z. Zhou, J. Stewart, and E. S. Kleinerman (2005)
Clin. Cancer Res. 11, 2008-2017
 |  Abstract »  |  Full Text »  |  PDF »

A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2.

B. Jiang, W. Liu, H. Qu, L. Meng, S. Song, T. Ouyang, and C. Shou (2005)
J. Biol. Chem. 280, 4656-4662
 |  Abstract »  |  Full Text »  |  PDF »

Conformational HER-2/neu B-cell Epitope Peptide Vaccine Designed to Incorporate Two Native Disulfide Bonds Enhances Tumor Cell Binding and Antitumor Activities.

N. K. Dakappagari, K. D. Lute, S. Rawale, J. T. Steele, S. D. Allen, G. Phillips, R. T. Reilly, and P. T. P. Kaumaya (2005)
J. Biol. Chem. 280, 54-63
 |  Abstract »  |  Full Text »  |  PDF »

Her-2/neu Overexpression and Amplification in Uterine Papillary Serous Carcinoma.

B. M. Slomovitz, R. R. Broaddus, T. W. Burke, N. Sneige, P. T. Soliman, W. Wu, C. C. Sun, M. F. Munsell, D. M. Gershenson, and K. H. Lu (2004)
J. Clin. Oncol. 22, 3126-3132
 |  Abstract »  |  Full Text »  |  PDF »

HER-2, gp100, and MAGE-1 Are Expressed in Human Glioblastoma and Recognized by Cytotoxic T Cells.

G. Liu, H. Ying, G. Zeng, C. J. Wheeler, K. L. Black, and J. S. Yu (2004)
Cancer Res. 64, 4980-4986
 |  Abstract »  |  Full Text »  |  PDF »

Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine kinase ErbB-2.

J. M. Swiercz, R. Kuner, and S. Offermanns (2004)
J. Cell Biol. 165, 869-880
 |  Abstract »  |  Full Text »  |  PDF »

Radiolabeling, Biodistribution, and Dosimetry of 123I-mAb 14C5: A New mAb for Radioimmunodetection of Tumor Growth and Metastasis In Vivo.

C. M.M. Lahorte, K. Bacher, I. Burvenich, E. D. Coene, C. Cuvelier, C. De Potter, H. Thierens, C. Van de Wiele, R. A. Dierckx, and G. Slegers (2004)
J. Nucl. Med. 45, 1065-1073
 |  Abstract »  |  Full Text »  |  PDF »

High resolution microarray comparative genomic hybridisation analysis using spotted oligonucleotides.

B Carvalho, E Ouwerkerk, G A Meijer, and B Ylstra (2004)
J. Clin. Pathol. 57, 644-646
 |  Abstract »  |  Full Text »  |  PDF »

Caspase-8-Dependent HER-2 Cleavage in Response to Tumor Necrosis Factor {alpha} Stimulation Is Counteracted by Nuclear Factor {kappa}B through c-FLIP-L Expression.

V. Benoit, A. Chariot, L. Delacroix, V. Deregowski, N. Jacobs, M.-P. Merville, and V. Bours (2004)
Cancer Res. 64, 2684-2691
 |  Abstract »  |  Full Text »  |  PDF »

Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction.

C. Warburton, W. H. Dragowska, K. Gelmon, S. Chia, H. Yan, D. Masin, T. Denyssevych, A. E. Wallis, and M. B. Bally (2004)
Clin. Cancer Res. 10, 2512-2524
 |  Abstract »  |  Full Text »  |  PDF »

Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes.

K. Kono, E. Sato, H. Naganuma, A. Takahashi, K. Mimura, H. Nukui, and H. Fujii (2004)
Clin. Cancer Res. 10, 2538-2544
 |  Abstract »  |  Full Text »  |  PDF »

Negative Regulation of HER2 Signaling by the PEST-type Protein-tyrosine Phosphatase BDP1.

M. Gensler, M. Buschbeck, and A. Ullrich (2004)
J. Biol. Chem. 279, 12110-12116
 |  Abstract »  |  Full Text »  |  PDF »

The N-terminal Region of NTAK/Neuregulin-2 Isoforms Has an Inhibitory Activity on Angiogenesis.

N. Nakano, S. Higashiyama, H. Ohmoto, H. Ishiguro, N. Taniguchi, and Y. Wada (2004)
J. Biol. Chem. 279, 11465-11470
 |  Abstract »  |  Full Text »  |  PDF »

Monitoring of Serum Her-2/neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer.

W. J. Kostler, B. Schwab, C. F. Singer, R. Neumann, E. Rucklinger, T. Brodowicz, S. Tomek, M. Niedermayr, M. Hejna, G. G. Steger, et al. (2004)
Clin. Cancer Res. 10, 1618-1624
 |  Abstract »  |  Full Text »  |  PDF »

HER2 Expression in Salivary Gland Carcinomas: Dependence on Histological Subtype.

B. Glisson, A. D. Colevas, R. Haddad, J. Krane, A. El-Naggar, M. Kies, R. Costello, C. Summey, M. Arquette, C. Langer, et al. (2004)
Clin. Cancer Res. 10, 944-946
 |  Abstract »  |  Full Text »  |  PDF »

Clinical Cardiac Tolerability of Trastuzumab.

E. A. Perez and R. Rodeheffer (2004)
J. Clin. Oncol. 22, 322-329
 |  Abstract »  |  Full Text »  |  PDF »

HER-2/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway.

F. Herrmann, H.-A. Lehr, I. Drexler, G. Sutter, J. Hengstler, U. Wollscheid, and B. Seliger (2004)
Cancer Res. 64, 215-220
 |  Abstract »  |  Full Text »  |  PDF »

Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells.

F. Leone, E. Perissinotto, G. Cavalloni, V. Fonsato, S. Bruno, N. Surrenti, D. Hong, A. Capaldi, M. Geuna, W. Piacibello, et al. (2003)
J. Leukoc. Biol. 74, 593-601
 |  Abstract »  |  Full Text »  |  PDF »

Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer.

W. P. Carney, R. Neumann, A. Lipton, K. Leitzel, S. Ali, and C. P. Price (2003)
Clin. Chem. 49, 1579-1598
 |  Abstract »  |  Full Text »  |  PDF »

Gene Expression Profiling of Neu-induced Mammary Tumors from Transgenic Mice Reveals Genetic and Morphological Similarities to ErbB2-expressing Human Breast Cancers.

E. R. Andrechek, M. A. Laing, A. A. Girgis-Gabardo, P. M. Siegel, R. D. Cardiff, and W. J. Muller (2003)
Cancer Res. 63, 4920-4926
 |  Abstract »  |  Full Text »  |  PDF »

Comparison of Two Quantitative Polymerase Chain Reaction Methods for Detecting HER2/neu Amplification.

A. Millson, A. Suli, L. Hartung, S. Kunitake, A. Bennett, M. C. L. Nordberg, W. Hanna, C. T. Wittwer, A. Seth, and E. Lyon (2003)
J. Mol. Diagn. 5, 184-190
 |  Abstract »  |  Full Text »  |  PDF »

Trastuzumab and Interleukin-2 in HER2-positive Metastatic Breast Cancer: A Pilot Study.

T. Repka, E. G. Chiorean, J. Gay, K. E. Herwig, V. K. Kohl, D. Yee, and J. S. Miller (2003)
Clin. Cancer Res. 9, 2440-2446
 |  Abstract »  |  Full Text »  |  PDF »

Prognostic Significance of p53, nm23, PCNA and c-erbB-2 in Gastric Cancer.

K. E. Lee, H.-J. Lee, Y. H. Kim, H. J. Yu, H.-K. Yang, W.-H. Kim, K. U. Lee, K. J. Choe, and J.-P. Kim (2003)
Jpn. J. Clin. Oncol. 33, 173-179
 |  Abstract »  |  Full Text »  |  PDF »

Human Epidermal Receptor-2 Expression in Prostate Cancer.

B. F. Calvo, A. M. Levine, M. Marcos, Q. F. Collins, M. V. Iacocca, L. S. Caskey, C. W. Gregory, Y. Lin, Y. E. Whang, H. S. Earp, et al. (2003)
Clin. Cancer Res. 9, 1087-1097
 |  Abstract »  |  Full Text »  |  PDF »

Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention.

R. Nahta, G. N. Hortobagyi, and F. J. Esteva (2003)
Oncologist 8, 5-17
 |  Abstract »  |  Full Text »  |  PDF »

Active Signaling by HER-2/neu in a Subpopulation of HER-2/neu-overexpressing Ductal Carcinoma in Situ: Clinicopathological Correlates.

M. P. DiGiovanna, P. Chu, T. L. Davison, C. L. Howe, D. Carter, E. B. Claus, and D. F. Stern (2002)
Cancer Res. 62, 6667-6673
 |  Abstract »  |  Full Text »  |  PDF »

In vitro comparative evaluation of trastuzumab (Herceptin(R)) combined with paclitaxel (Taxol(R)) or docetaxel (Taxotere(R)) in HER2-expressing human breast cancer cell lines.

J.-L. Merlin, M. Barberi-Heyob, and N. Bachmann (2002)
Ann. Onc. 13, 1743-1748
 |  Abstract »  |  Full Text »  |  PDF »

Dendritic Cells Pulsed with HER-2/neu-derived Peptides Can Induce Specific T-Cell Responses in Patients with Gastric Cancer.

K. Kono, A. Takahashi, H. Sugai, H. Fujii, A. R. Choudhury, R. Kiessling, and Y. Matsumoto (2002)
Clin. Cancer Res. 8, 3394-3400
 |  Abstract »  |  Full Text »  |  PDF »

Visualization of Effective Tumor Targeting by CD8+ Natural Killer T Cells Redirected with Bispecific Antibody F(ab')2HER2xCD3.

C. Scheffold, M. Kornacker, Y. C. Scheffold, C. H. Contag, and R. S. Negrin (2002)
Cancer Res. 62, 5785-5791
 |  Abstract »  |  Full Text »  |  PDF »

c-erb B-2 Expression Is Associated with Tumor Location and Venous Invasion and Influences Survival of Patients with Gastric Carcinoma.

J. Pinto-de-Sousa, L. David, R. Almeida, D. Leitao, J. R. Preto, M. Seixas, and A. Pimenta (2002)
International Journal of Surgical Pathology 10, 247-256
 |  Abstract »  |  PDF »

Basolateral Targeting of ERBB2 Is Dependent on a Novel Bipartite Juxtamembrane Sorting Signal but Independent of the C-Terminal ERBIN-Binding Domain.

C. Dillon, A. Creer, K. Kerr, A. Kumin, and C. Dickson (2002)
Mol. Cell. Biol. 22, 6553-6563
 |  Abstract »  |  Full Text »  |  PDF »

Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens.

M. F. Press, D. J. Slamon, K. J. Flom, J. Park, J.-Y. Zhou, and L. Bernstein (2002)
J. Clin. Oncol. 20, 3095-3105
 |  Abstract »  |  Full Text »  |  PDF »

ErbB2 Is Required for Muscle Spindle and Myoblast Cell Survival.

E. R. Andrechek, W. R. Hardy, A. A. Girgis-Gabardo, R. L. S. Perry, R. Butler, F. L. Graham, R. C. Kahn, M. A. Rudnicki, and W. J. Muller (2002)
Mol. Cell. Biol. 22, 4714-4722
 |  Abstract »  |  Full Text »  |  PDF »

"Build Quality in"--HER2 Testing in the Real World.

J. A. Zujewski (2002)
J Natl Cancer Inst 94, 788-789
 |  Full Text »  |  PDF »

Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay.

G. Curigliano, M. Colleoni, G. Renne, G. Mazzarol, R. Gennari, G. Peruzzotti, F. de Braud, C. Robertson, E. Maiorano, P. Veronesi, et al. (2002)
Ann. Onc. 13, 895-902
 |  Abstract »  |  Full Text »  |  PDF »

Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide-Based Vaccines.

M. L. Disis, T. A. Gooley, K. Rinn, D. Davis, M. Piepkorn, M. A. Cheever, K. L. Knutson, and K. Schiffman (2002)
J. Clin. Oncol. 20, 2624-2632
 |  Abstract »  |  Full Text »  |  PDF »

A New Human Antitumor Immunoreagent Specific for ErbB2.

C. De Lorenzo, D. B. Palmer, R. Piccoli, M. A. Ritter, and G. D'Alessio (2002)
Clin. Cancer Res. 8, 1710-1719
 |  Abstract »  |  Full Text »  |  PDF »

HER-2/neu and hTERT Cryptic Epitopes as Novel Targets for Broad Spectrum Tumor Immunotherapy.

A. Scardino, D.-A. Gross, P. Alves, J. L. Schultze, S. Graff-Dubois, O. Faure, S. Tourdot, S. Chouaib, L. M. Nadler, F. A. Lemonnier, et al. (2002)
J. Immunol. 168, 5900-5906
 |  Abstract »  |  Full Text »  |  PDF »

Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

M M de Jong, I M Nolte, G J te Meerman, W T A van der Graaf, J C Oosterwijk, J H Kleibeuker, M Schaapveld, and E G E de Vries (2002)
J. Med. Genet. 39, 225-242
 |  Abstract »  |  Full Text »  |  PDF »

Early Placenta Insulin-like Growth Factor (pro-EPIL) Is Overexpressed and Secreted by c-erbB-2-positive Cells with High Invasion Potential.

B. Brandt, A. Roetger, J.-M. Bidart, J. Packeisen, K. Schier, J.-H. Mikesch, D. Kemming, W. Boecker, D. Yu, and H. Buerger (2002)
Cancer Res. 62, 1020-1024
 |  Abstract »  |  Full Text »  |  PDF »

Automated Electrorotation to Reveal Dielectric Variations Related to HER-2/neu Overexpression in MCF-7 Sublines.

M. Cristofanilli, G. De Gasperis, L. Zhang, M.-C. Hung, P. R. C. Gascoyne, and G. N. Hortobagyi (2002)
Clin. Cancer Res. 8, 615-619
 |  Abstract »  |  Full Text »  |  PDF »

Significance of, and Optimal Screening for, HER-2 Gene Amplification and Protein Overexpression in Breast Carcinoma.

W. K. Funkhouser and K. Kaiser-Rogers (2001)
Ann. Clin. Lab. Sci. 31, 349-358
 |  Abstract »  |  Full Text »  |  PDF »

RRR-{alpha}-Tocopheryl Succinate Induces MDA-MB-435 and MCF-7 Human Breast Cancer Cells to Undergo Differentiation.

H. You, W. Yu, B. G. Sanders, and K. Kline (2001)
Cell Growth Differ. 12, 471-480
 |  Abstract »  |  Full Text »  |  PDF »

Is Circulating HER-2 More Than Just a Tumor Marker?.

J. Baselga (2001)
Clin. Cancer Res. 7, 2605-2607
 |  Full Text »  |  PDF »

Her-2/neu Overexpression in Muscle-invasive Urothelial Carcinoma of the Bladder: Prognostic Significance and Comparative Analysis in Primary and Metastatic Tumors.

R. E. Jimenez, M. Hussain, F. J. Bianco Jr., U. Vaishampayan, P. Tabazcka, W. A. Sakr, J. E. Pontes, D. P. Wood Jr., and D. J. Grignon (2001)
Clin. Cancer Res. 7, 2440-2447
 |  Abstract »  |  Full Text »  |  PDF »

Novel Compounds in the Therapy of Breast Cancer: Opportunities for Integration with Docetaxel.

A. W. Tolcher (2001)
Oncologist 6, 40-44
 |  Abstract »  |  Full Text »  |  PDF »

Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification.

A. D. Seidman, M. N. Fornier, F. J. Esteva, L. Tan, S. Kaptain, A. Bach, K. S. Panageas, C. Arroyo, V. Valero, V. Currie, et al. (2001)
J. Clin. Oncol. 19, 2587-2595
 |  Abstract »  |  Full Text »  |  PDF »

Cloning of a novel EGFR-related peptide: a putative negative regulator of EGFR.

Y. Yu, A. K. Rishi, J. R. Turner, D. Liu, E. D. Black, J. A. Moshier, and A. P. N. Majumdar (2001)
Am J Physiol Cell Physiol 280, C1083-C1089
 |  Abstract »  |  Full Text »  |  PDF »

Identification of Epitope Regions Recognized by Tumor Inhibitory and Stimulatory Anti-ErbB-2 Monoclonal Antibodies: Implications for Vaccine Design.

Y. L. Yip, G. Smith, J. Koch, S. Dubel, and R. L. Ward (2001)
J. Immunol. 166, 5271-5278
 |  Abstract »  |  Full Text »  |  PDF »

Comparison of Methods of Measuring HER-2 in Metastatic Breast Cancer Patients Treated With High-Dose Chemotherapy.

L. N. Harris, V. Liotcheva, G. Broadwater, M. J. Ramirez, P. Maimonis, S. Anderson, T. Everett, D. Harpole, M. B. Moore, D. A. Berry, et al. (2001)
J. Clin. Oncol. 19, 1698-1706
 |  Abstract »  |  Full Text »  |  PDF »

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2.

D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, et al. (2001)
N. Engl. J. Med. 344, 783-792
 |  Abstract »  |  Full Text »  |  PDF »

erbB2 Overexpression on Occult Metastatic Cells in Bone Marrow Predicts Poor Clinical Outcome of Stage I-III Breast Cancer Patients.

S. Braun, G. Schlimok, I. Heumos, G. Schaller, L. Riethdorf, G. Riethmüller, and K. Pantel (2001)
Cancer Res. 61, 1890-1895
 |  Abstract »  |  Full Text »

Overexpression of HER-2 in Ovarian Carcinomas.

I. Hellström, G. Goodman, J. Pullman, Y. Yang, and K. E. Hellström (2001)
Cancer Res. 61, 2420-2423
 |  Abstract »  |  Full Text »

The Association of HER-2/neu Amplification With Breast Cancer Recurrence.

J. A. Carr, S. Havstad, R. J. Zarbo, G. Divine, P. Mackowiak, and V. Velanovich (2000)
Arch Surg 135, 1469-1474
 |  Abstract »  |  Full Text »  |  PDF »

Recombinant Anti-Human HER2/neu IgG3-(GM-CSF) Fusion Protein Retains Antigen Specificity and Cytokine Function and Demonstrates Antitumor Activity.

J. S. Dela Cruz, K. R. Trinh, S. L. Morrison, and M. L. Penichet (2000)
J. Immunol. 165, 5112-5121
 |  Abstract »  |  Full Text »  |  PDF »

Prognostic Value of the Type I Growth Factor Receptors in a Large Series of Human Primary Breast Cancers Quantified with a Real-Time Reverse Transcription-Polymerase Chain Reaction Assay.

V. Pawlowski, F. Revillion, M. Hebbar, L. Hornez, and J.-P. Peyrat (2000)
Clin. Cancer Res. 6, 4217-4225
 |  Abstract »  |  Full Text »  |  PDF »

HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor-Positive, Node-Positive Breast Cancer.

D. A. Berry, H. B. Muss, A. D. Thor, L. Dressler, E. T. Liu, G. Broadwater, D. R. Budman, I. C. Henderson, M. Barcos, D. Hayes, et al. (2000)
J. Clin. Oncol. 18, 3471-3479
 |  Abstract »  |  Full Text »  |  PDF »

High-Throughput Tissue Microarray Analysis of Cyclin E Gene Amplification and Overexpression in Urinary Bladder Cancer.

J. Richter, U. Wagner, J. Kononen, A. Fijan, J. Bruderer, U. Schmid, D. Ackermann, R. Maurer, G. Alund, H. Knonagel, et al. (2000)
Am. J. Pathol. 157, 787-794
 |  Abstract »  |  Full Text »  |  PDF »

Prevention of Mammary Tumors with a Chimeric HER-2 B-cell Epitope Peptide Vaccine.

N. K. Dakappagari, D. B. Douglas, P. L. Triozzi, V. C. Stevens, and P. T. P. Kaumaya (2000)
Cancer Res. 60, 3782-3789
 |  Abstract »  |  Full Text »

A Natural ErbB4 Isoform That Does Not Activate Phosphoinositide 3-Kinase Mediates Proliferation but Not Survival or Chemotaxis.

V. Kainulainen, M. Sundvall, J. A. Maatta, E. Santiestevan, M. Klagsbrun, and K. Elenius (2000)
J. Biol. Chem. 275, 8641-8649
 |  Abstract »  |  Full Text »  |  PDF »

Population-Based, Case-Control Study of HER2 Genetic Polymorphism and Breast Cancer Risk.

D. Xie, X.-O. Shu, Z. Deng, W.-Q. Wen, K. E. Creek, Q. Dai, Y.-T. Gao, F. Jin, and W. Zheng (2000)
J Natl Cancer Inst 92, 412-417
 |  Abstract »  |  Full Text »  |  PDF »

Blocking HER-2/HER-3 Function with a Dominant Negative Form of HER-3 in Cells Stimulated by Heregulin and in Breast Cancer Cells with HER-2 Gene Amplification.

T. G. Ram, M. E. Schelling, and H. L. Hosick (2000)
Cell Growth Differ. 11, 173-183
 |  Abstract »  |  Full Text »

Nerve Growth Factor Cooperates with p185HER2 in Activating Growth of Human Breast Carcinoma Cells.

E. Tagliabue, F. Castiglioni, C. Ghirelli, M. Modugno, L. Asnaghi, G. Somenzi, C. Melani, and S. Menard (2000)
J. Biol. Chem. 275, 5388-5394
 |  Abstract »  |  Full Text »  |  PDF »

Characterization of a Repressor Element and a Juxtaposed Tissue-restricted Activator Element Located on the Distal neu Gene Promoter.

T.-C. Suen and P. E. Goss (2000)
J. Biol. Chem. 275, 6600-6607
 |  Abstract »  |  Full Text »  |  PDF »

To Advertise   |   Find Products